Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled treprostinil versus placebo in severe pulmonary arterial hypertension
2004-003236-59Phase 3Completed
- Sponsor
- United Therapeutics Corporation
- Start
- Jun 2005
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pulmonary arterial hypertension (PAH) comparing Inhaled treprostinil with Placebo (2 arms). Primary endpoint: Change in peak unencouraged 6-minute walk test distance at 12 weeks. Started Jun 2005; status: completed.
02
Drugs
treprostinil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2004-003236-59.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-003236-59.